ATF6α Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma()()

Patients with metastatic or relapsed/refractory osteosarcoma (OS) have a 5-year survival rate of <30%. This has remained unchanged over several decades. One of the factors contributing to lack of improvement in survival is the development of chemoresistance. Hence, elucidating and targeting the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarapureddy, Suma, Abril, Jazmine, Foote, Janet, Kumar, Saravana, Asad, Omar, Sharath, Veena, Faraj, Janine, Daniel, Dustin, Dickman, Paul, White-Collins, Andrea, Hingorani, Pooja, Sertil, Aparna R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484364/
https://www.ncbi.nlm.nih.gov/pubmed/31029032
http://dx.doi.org/10.1016/j.neo.2019.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484364/
https://www.ncbi.nlm.nih.gov/pubmed/31029032
http://dx.doi.org/10.1016/j.neo.2019.02.004

Ejemplares similares